Table 1.
Baseline Characteristics of the Study Subjects According to their NAFLD Status.
| Characteristics | NAFLD | P | |
|---|---|---|---|
| Yes (n = 2830) | No (n = 3410) | ||
| Age (years) | 50.49 ± 8.13 | 50.90 ± 8.22 | 0.049 |
| Height (cm) | 168.46 ± 7.75 | 166.08 ± 8.15 | <0.001 |
| Weight (kg) | 73.62 ± 10.21 | 65.18 ± 9.96 | <0.001 |
| BMI (kg/m2 | 25.87 ± 2.57 | 23.54 ± 2.50 | <0.001 |
| HbA1c (%) | 5.66 ± 0.36 | 5.58 ± 0.36 | <0.001 |
| FPG (mg/dL) | 103.72 ± 8.75 | 101.43 ± 8.50 | <0.001 |
| Waist circumference (cm) | 88.08 ± 6.96 | 80.66 ± 7.65 | <0.001 |
| SBP (mmHg) | 123.22 ± 13.61 | 119.40 ± 14.11 | <0.001 |
| DBP (mmHg) | 77.09 ± 8.80 | 74.21 ± 8.75 | <0.001 |
| Total cholesterol (mg/dL) | 200.91 ± 33.63 | 192.74 ± 32.39 | <0.001 |
| Triglycerides (mg/dL) | 176.92 ± 108.29 | 118.96 ± 63.81 | <0.001 |
| HDL cholesterol (mg/dL) | 50.94 ± 11.31 | 58.68 ± 14.36 | <0.001 |
| LDL cholesterol (mg/dL) | 131.60 ± 29.85 | 123.10 ± 28.63 | <0.001 |
| Insulin (µIU)† | 10.11 ± 5.14 | 6.86 ± 3.41 | <0.001 |
| HOMA-IR† | 2.60 ± 1.38 | 1.73 ± 0.90 | <0.001 |
| AST (IU/L) | 27.41 ± 19.86 | 23.30 ± 10.43 | <0.001 |
| ALT, (IU/L) | 31.62 ± 32.22 | 20.96 ± 16.60 | <0.001 |
| Creatinine (mg/dL) | 0.93 ± 0.16 | 0.89 ± 0.17 | <0.001 |
| % | |||
| Sex | <0.001 | ||
| Male | 2351 (83.1) | 2243 (65.8) | |
| Female | 479 (16.9) | 1167 (34.2) | |
| Current smoker | <0.001 | ||
| Yes | 1916 (67.7) | 1777 (52.1) | |
| No | 914 (32.3) | 1633 (47.9) | |
| Current alcohol drinker | <0.001 | ||
| Yes | 1580 (55.8) | 1618 (47.4) | |
| No | 1250 (44.2) | 1792 (52.6) | |
| Overweight/obese | <0.001 | ||
| Yes | 2518 (89.0) | 1975 (57.9) | |
| No | 312 (11.0) | 1435 (42.1) | |
| Hypertension | <0.001 | ||
| Yes | 1302 (46.0) | 1107 (32.5) | |
| No | 1528 (54.0) | 2303 (67.5) | |
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; LDL cholesterol, low-density lipoprotein cholesterol; HDL cholesterol, high-density lipoprotein cholesterol; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
†Insulin levels and HOMA-IR were not available for 1375 patients.